Management of Cutaneous Polyarteritis Nodosa

Disease Classification and Treatment Approach

The American College of Rheumatology recommends treating cutaneous PAN with non-glucocorticoid immunosuppressive agents (azathioprine or methotrexate) combined with glucocorticoids rather than glucocorticoids alone, to minimize steroid toxicity while effectively controlling disease activity 1, 2
Cutaneous PAN is classified as nonsevere disease because it lacks life- or organ-threatening manifestations, presenting instead with uncomplicated cutaneous disease such as nodules, livedo reticularis, and ulcerations, according to the American College of Rheumatology 3, 1

The American College of Rheumatology recommends combination therapy with non-glucocorticoid immunosuppressive agents plus glucocorticoids over glucocorticoid monotherapy, due to the glucocorticoid-sparing effect and improved disease control 1, 2
Adding immunosuppressive agents allows for lower cumulative steroid doses, reducing long-term toxicity, as suggested by the American College of Rheumatology 2, 4
Upfront combination treatment is more practical, as some patients achieve remission with steroids alone, but a substantial number ultimately require additional therapy, according to the American College of Rheumatology 2, 4

The American College of Rheumatology recommends moderate-dose oral glucocorticoids, such as prednisone 0.25–0.5 mg/kg/day (adults; generally 10–40 mg/day), for cutaneous PAN 3, 1
Azathioprine is the preferred first-line agent, and methotrexate is an alternative first-line agent, according to the American College of Rheumatology 1, 2
Mycophenolate mofetil has not been well studied in PAN and should be avoided, as recommended by the American College of Rheumatology 2, 4

The American College of Rheumatology recommends discontinuing non-glucocorticoid immunosuppressive therapy after 18 months of sustained remission, rather than continuing indefinitely, to balance the risk of relapse against the cumulative toxicity of prolonged immunosuppression 1, 5

The American College of Rheumatology recommends serial clinical examinations to assess skin lesions, pain, and systemic symptoms, as well as regular assessment for development of systemic manifestations that would reclassify the disease as severe 1, 3, 1
Monitoring for glucocorticoid-related adverse effects, particularly with prolonged use, is also recommended by the American College of Rheumatology 2

The American College of Rheumatology recommends not treating cutaneous PAN with cyclophosphamide unless it progresses to severe systemic disease with organ-threatening manifestations, as cyclophosphamide is reserved for severe PAN and exposes patients to unnecessary toxicity when used for isolated cutaneous disease 2, 4
Superficial skin punch biopsies should not be used for diagnosis, as they miss the medium-sized vessels in the deep dermis where the pathology occurs, according to the American College of Rheumatology 6, 3, 7